U.S. markets closed
  • S&P 500

    4,223.70
    -22.89 (-0.54%)
     
  • Dow 30

    34,033.67
    -265.66 (-0.77%)
     
  • Nasdaq

    14,039.68
    -33.22 (-0.24%)
     
  • Russell 2000

    2,314.69
    -5.38 (-0.23%)
     
  • Crude Oil

    71.46
    -0.69 (-0.96%)
     
  • Gold

    1,818.70
    -42.70 (-2.29%)
     
  • Silver

    27.27
    -0.54 (-1.95%)
     
  • EUR/USD

    1.1998
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • GBP/USD

    1.3990
    +0.0003 (+0.02%)
     
  • USD/JPY

    110.7150
    +0.1020 (+0.09%)
     
  • BTC-USD

    38,468.37
    -1,672.79 (-4.17%)
     
  • CMC Crypto 200

    961.10
    -31.37 (-3.16%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

The impact of lowering prescription drug prices

  • Oops!
    Something went wrong.
    Please try again later.

For all the polarization in American politics, one thing both sides of the aisle seem to agree on -- prescription drug prices are too high. Kirsten Axelsen a former Pfizer executive and now a visiting fellow at the American Enterprise Institute, joined The Final Round to discuss why she thinks the current system is flawed, but that proposed legislation from the democrats will curtail investment in new therapies.